Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped

Source The Motley Fool

Novo Nordisk (NYSE: NVO) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem less than thrilled:

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is spending $2 billion to license an entirely different GLP-1 drug from China.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, respectively.

Rolling back prices on Wegovy

Let's take Novo Nordisk's news items one at a time, starting with Wegovy. Novo Nordisk announced earlier this month that its NovoCare Pharmacy would sell Wegovy direct to cash-paying consumers who don't use insurance to pay for their prescriptions. Each of the company's dose strengths would sell for $499 for a one-month supply. Today the company expanded the program, saying the $499 price will be available at local pharmacies, and not just for orders placed with NovoCare.

Previously, pharmacy cash sales were priced at $650 per month, so Novo has effectively cut prices by 23% for a big part of its market. Novo Nordisk investors may be worrying that Novo is losing market share, and may need to cut prices even further to compete with price cuts announced by Eli Lilly. Last month, Lilly cut the price of at least one dosage size of its competing Zepbound GLP-1 drug to $349, when purchased directly from Lilly.

Long story short, investors seem to be reading this news as bad for Novo (less revenue and maybe losing market share), but correspondingly good for Eli Lilly, which is still underpricing its rival on at least one dosage.

At the same time, Hims & Hers Health stock is continuing to gain strength on the back of reports out last week, that the company's exit from the GLP-1 market may not be as imminent as feared. On Wednesday last week, The Wall Street Journal reported that Hims & Hers "will keep offering pharmacy-made, or compounded, versions of Ozempic and Wegovy tweaked to individual prescriptions."

As the Journal explained, "current law ... allows compounding pharmacies to make special, individualized versions of drugs that aren't available commercially." So while Hims & Hers has benefited mightily from being able to mass market Ozempic, Wegovy, Mounjaro, and Zepbound lookalikes to fill a gap in supply from the drugs' inventors, and while that supply gap is going away, Hims & Hers may still be able to market copycat drugs in smaller quantities, and not be forced out of this market entirely after all. Such sales might even offer Hims & Hers better profit margins due to their personalization.

Novo and Lilly obviously aren't happy about this, and have filed lawsuits seeking to force drug compounders like Hims & Hers out of the market. But for the time being this legal question remains unresolved -- and Hims & Hers remains in the GLP-1 business.

Novo Nordisk goes big in China

In other news, Novo Nordisk announced today that has secured an exclusive license to develop, manufacture, and market UBT251, a weight loss drug from China's The United Bio-Technology (Hengqin) Co. Novo describes UBT251 as "a triple agonist of the receptors for GLP-1, GIP, and glucagon in early stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases."

Novo presumably hopes the three-pronged approach will perform even better than its current drugs Ozempic and Wegovy. Novo will pay its Chinese partner $200 million up front, and may pay a further $1.8 billion over time. It's a relatively small bet that could pay off bigly for Novo if it works. But it also highlights Novo's recent failures to improve its own drugs' performance without help.

Combined with positive news for Hims & Hers, and the potential threat to revenues from Novo lowering its prices, this helps explain why Novo Nordisk stock, in contrast to Eli Lilly and Hims & Hers, is losing ground today.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $305,226!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $41,382!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $517,876!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Continue »

*Stock Advisor returns as of March 24, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Gold Price Forecast: XAU/USD drifts higher above $4,200 as Fed delivers expected cut Gold price (XAU/USD) gains momentum to around $4,235 during the early Asian session on Thursday. The precious metal extends its upside after the US Federal Reserve (Fed) delivered an expected third consecutive interest rate cut and maintained its outlook for just one cut in 2026.

Author FXStreet

Dec 11, Thu

Gold price (XAU/USD) gains momentum to around $4,235 during the early Asian session on Thursday. The precious metal extends its upside after the US Federal Reserve (Fed) delivered an expected third consecutive interest rate cut and maintained its outlook for just one cut in 2026.

Gold remains bid as lack of Fed clarity and geopolitical frictions persist Gold (XAU/USD) advances modestly on Friday as traders seem to book profits ahead of the weekend, yet clings to gains of over 0.51% after reaching a seven-week high of $4,353. At the time of writing, XAU/USD trades at $4,302 as traders digest comments from Federal Reserve (Fed) officials.

Author FXStreet

Yesterday 01: 34

Gold (XAU/USD) advances modestly on Friday as traders seem to book profits ahead of the weekend, yet clings to gains of over 0.51% after reaching a seven-week high of $4,353. At the time of writing, XAU/USD trades at $4,302 as traders digest comments from Federal Reserve (Fed) officials.

Ethereum Price Slips Lower — $3,000 Looms as the Key Battleground Ethereum is attempting to recover from a $3,026 low but remains below $3,200 and the 100-hour SMA, with a bearish trend line near $3,175 capping rebounds as bulls need a clean break above $3,200 to target $3,250–$3,400, while a drop below $3,050 risks a retest of $3,000 and $2,940.

Author Mitrade

Yesterday 03: 25

Ethereum is attempting to recover from a $3,026 low but remains below $3,200 and the 100-hour SMA, with a bearish trend line near $3,175 capping rebounds as bulls need a clean break above $3,200 to target $3,250–$3,400, while a drop below $3,050 risks a retest of $3,000 and $2,940.

Macro Analysts: Hawkish Japan Could Push Bitcoin Below $70K Analysts predict Bitcoin may face further declines towards the $70,000 mark if the Bank of Japan raises interest rates as expected.

Author Mitrade

Yesterday 05: 48

Analysts predict Bitcoin may face further declines towards the $70,000 mark if the Bank of Japan raises interest rates as expected.

Bitcoin Slides 5% as Sellers Lean In — Can BTC Reclaim $88,000?Bitcoin has dropped back below $88,000 after rolling over from $90,500, with price still trading under the 100-hour Simple Moving Average. The sell-off found a floor at $85,151, and BTC is now consolidating near that base, but rebounds are facing pressure from a bearish trend line around $89,000. Bulls need to retake $88,000–$89,000 to ease downside risk; failure to do so keeps $85,500–$85,000 and then $83,500 in play, with $80,000 as the deeper “line in the sand.” Bitcoin (BTC) is back in damage-control mode after a sharp pullback wiped out recent gains. The price failed to reclaim the $90,000–$90,500 band, rolled over, and slid through $88,500 before briefly dipping under $87,000. Buyers did show up around $85,000, but the rebound so far looks more like stabilization than a clear trend reversal. Bitcoin dips hard, finds a bid near $85,000（h3） BTC’s latest move lower began when it couldn’t build follow-through above $90,000 and $90,500. Once that upside stalled, sellers took control and pushed price down through $88,500. The slide accelerated enough to spike below $87,000, but the market didn’t free-fall. Bulls defended the $85,000 zone, printing a low at $85,151. Since then, Bitcoin has been consolidating below the 23.6% Fibonacci retracement of the drop from the $93,560 swing high to the $85,151 low — a clue that the bounce is still shallow and that sellers haven’t fully backed off yet. Structurally, BTC is still on the back foot: It’s trading below $88,000, and It remains below the 100-hour Simple Moving Average, keeping short-term trend pressure pointed downward. Resistance is layered, and $89,000 is the problem area（h3） If bulls try to turn this into a recovery, they’ll have to climb through multiple ceilings in quick succession. First, BTC faces resistance around $87,150, followed by a more meaningful barrier near $87,500. From there, the market’s attention snaps back to $88,000 — the level BTC just lost and now needs to reclaim. A close back above $88,000 would improve the tone, but it doesn’t solve the bigger issue: there’s a bearish trend line on the hourly BTC/USD chart (Kraken feed) with resistance near $89,000, which also lines up with the next technical hurdle. If BTC can push through $89,000 and hold, the rebound could extend toward $90,000, with follow-through targets at $91,000 and $91,500. But until price clears that $88,000–$89,000 zone, rallies are at risk of being sold rather than chased. If BTC fails to reclaim resistance, the downside path is clear（h3） The near-term bear case is simple: if Bitcoin can’t climb back above the $87,000 area and keep traction, sellers may attempt another leg lower. Support levels line up like this: Immediate support: $85,500 First major support: $85,000 Next support: $83,500 Then $82,500 in the near term Below that, the major “don’t break this” level is still $80,000. If BTC slips under $80,000, the risk of acceleration to the downside increases significantly — not because it’s magic, but because it’s the kind of psychological and structural level that tends to trigger forced de-risking. Indicators: momentum still leans bearish（h3） The intraday indicators aren’t offering much comfort yet: Hourly MACD is losing pace in the bearish zone. Hourly RSI remains below 50, suggesting sellers still have the upper hand on short timeframes. So while the $85,000 defense held for now, the market hasn’t flipped bullish — it’s just stopped bleeding.

Author Mitrade

3 hours ago

Bitcoin has dropped back below $88,000 after rolling over from $90,500, with price still trading under the 100-hour Simple Moving Average. The sell-off found a floor at $85,151, and BTC is now consolidating near that base, but rebounds are facing pressure from a bearish trend line around $89,000. Bulls need to retake $88,000–$89,000 to ease downside risk; failure to do so keeps $85,500–$85,000 and then $83,500 in play, with $80,000 as the deeper “line in the sand.” Bitcoin (BTC) is back in damage-control mode after a sharp pullback wiped out recent gains. The price failed to reclaim the $90,000–$90,500 band, rolled over, and slid through $88,500 before briefly dipping under $87,000. Buyers did show up around $85,000, but the rebound so far looks more like stabilization than a clear trend reversal. Bitcoin dips hard, finds a bid near $85,000（h3） BTC’s latest move lower began when it couldn’t build follow-through above $90,000 and $90,500. Once that upside stalled, sellers took control and pushed price down through $88,500. The slide accelerated enough to spike below $87,000, but the market didn’t free-fall. Bulls defended the $85,000 zone, printing a low at $85,151. Since then, Bitcoin has been consolidating below the 23.6% Fibonacci retracement of the drop from the $93,560 swing high to the $85,151 low — a clue that the bounce is still shallow and that sellers haven’t fully backed off yet. Structurally, BTC is still on the back foot: It’s trading below $88,000, and It remains below the 100-hour Simple Moving Average, keeping short-term trend pressure pointed downward. Resistance is layered, and $89,000 is the problem area（h3） If bulls try to turn this into a recovery, they’ll have to climb through multiple ceilings in quick succession. First, BTC faces resistance around $87,150, followed by a more meaningful barrier near $87,500. From there, the market’s attention snaps back to $88,000 — the level BTC just lost and now needs to reclaim. A close back above $88,000 would improve the tone, but it doesn’t solve the bigger issue: there’s a bearish trend line on the hourly BTC/USD chart (Kraken feed) with resistance near $89,000, which also lines up with the next technical hurdle. If BTC can push through $89,000 and hold, the rebound could extend toward $90,000, with follow-through targets at $91,000 and $91,500. But until price clears that $88,000–$89,000 zone, rallies are at risk of being sold rather than chased. If BTC fails to reclaim resistance, the downside path is clear（h3） The near-term bear case is simple: if Bitcoin can’t climb back above the $87,000 area and keep traction, sellers may attempt another leg lower. Support levels line up like this: Immediate support: $85,500 First major support: $85,000 Next support: $83,500 Then $82,500 in the near term Below that, the major “don’t break this” level is still $80,000. If BTC slips under $80,000, the risk of acceleration to the downside increases significantly — not because it’s magic, but because it’s the kind of psychological and structural level that tends to trigger forced de-risking. Indicators: momentum still leans bearish（h3） The intraday indicators aren’t offering much comfort yet: Hourly MACD is losing pace in the bearish zone. Hourly RSI remains below 50, suggesting sellers still have the upper hand on short timeframes. So while the $85,000 defense held for now, the market hasn’t flipped bullish — it’s just stopped bleeding.

Popular Articles

Popular Articles

Popular Articles

Popular Articles

Popular Articles

Popular Articles

Popular Articles

Popular Articles

Popular Analysis

Popular Analysis

Popular Analysis

Popular Analysis

Popular Analysis

Popular Analysis

Top Blog Posts

Top Blog Posts

Top Blog Posts

Top Blog Posts

Top Blog Posts

Top Blog Posts

Top Blog Posts

Beginners

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped

Rolling back prices on Wegovy

Novo Nordisk goes big in China

Don’t miss this second chance at a potentially lucrative opportunity

Recommended Articles